- New research demonstrates the long-term effectiveness of injectable semaglutide (Ozempic and Wegovy) at improving blood sugar control and weight loss in people with type 2 diabetes.
- There’s also promising news surrounding tirzepatide (Mounjaro) when it comes to managing type 2 diabetes.
- Experts say that with obesity rates rising in correlation with type 2 diabetes, finding new ways to treat the disease is critical.
New data shows that drugs such as Ozempic and Wegovy are effective for up to three years when it comes to managing weight and blood sugar in people with type 2 diabetes.
In findings presented this week at the annual meeting of the European Association for the Study of Diabetes (EASD), researchers reported that injectable semaglutide – sold under the trade names of Ozempic and Wegovy – can be helpful for long-term type 2 diabetes management with just a single weekly shot.
“Semaglutide is given once weekly and grants patients with type 2 diabetes improved glucose control and weight loss,” explained Avraham Karasik a lead study author and professor at the Institute of Research and Innovation at Maccabi Health Services in Israel. “Patients enjoy both weight-dependent decrease in blood glucose, in addition to the benefits of decreased weight and direct cardiovascular advantages.”
The research was funded by Novo Nordisk, the manufacturers of Ozempic. It also hasn’t been published yet in a peer-reviewed journal.
Nonetheless, an expert interviewed by Medical News Today says the research is one more indication that treatments for type 2 diabetes have come a long way in recent years.
Karasik told Medical News Today that study participants with lower adherence, in general, will see their glucose levels rise with time, and this was observed in the study.
Still, there was an intriguing wrinkle.
“Surprisingly, this was not accompanied by a parallel rise in weight, which stayed relatively stable through the follow-up period,” he said.
This means, Karasik…
Read the full article here